These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 20453011)

  • 1. Doctors warn against using Avastin for macular degeneration.
    Kmietowicz Z
    BMJ; 2010 May; 340():c2483. PubMed ID: 20453011
    [No Abstract]   [Full Text] [Related]  

  • 2. Why using Avastin for eye disease is so difficult.
    Torjesen I
    BMJ; 2012 May; 344():e3012. PubMed ID: 22549057
    [No Abstract]   [Full Text] [Related]  

  • 3. Bevacizumab and ranibizumab. Bevacizumab and the inverse postcode lottery.
    Harris MJ
    BMJ; 2010 Jul; 341():c3718. PubMed ID: 20627986
    [No Abstract]   [Full Text] [Related]  

  • 4. Off-label prescribing in macular degeneration.
    McCartney M
    BMJ; 2011 Oct; 343():d6778. PubMed ID: 22012651
    [No Abstract]   [Full Text] [Related]  

  • 5. Cancer drug offers effective, cheaper option for AMD.
    Stephenson J
    JAMA; 2011 May; 305(20):2053-4. PubMed ID: 21610231
    [No Abstract]   [Full Text] [Related]  

  • 6. Position paper: the need for head-to-head studies comparing Avastin versus Lucentis.
    Schmucker C; Antes G; Lelgemann M
    Surv Ophthalmol; 2009; 54(6):705-7. PubMed ID: 19818262
    [No Abstract]   [Full Text] [Related]  

  • 7. [A new drug for macular degeneration. A breakthrough accomplished (interview by Waldtraud Paukstadt)].
    Holz FG
    MMW Fortschr Med; 2007 Jan; 149(3):13-4. PubMed ID: 17619376
    [No Abstract]   [Full Text] [Related]  

  • 8. Avastin is as effective as Lucentis for wet AMD and could save NHS 84m pound a year, study shows.
    Hawkes N
    BMJ; 2012 May; 344():e3275. PubMed ID: 22573655
    [No Abstract]   [Full Text] [Related]  

  • 9. Saving money on the PBS: ranibizumab or bevacizumab for neovascular macular degeneration?
    Harvey KJ; Day RO; Campbell WG; Lipworth W
    Med J Aust; 2011 Jun; 194(11):567-8. PubMed ID: 21644867
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ranibizumab (Lucentis) versus bevacizumab (Avastin): modelling cost effectiveness.
    Raftery J; Clegg A; Jones J; Tan SC; Lotery A
    Br J Ophthalmol; 2007 Sep; 91(9):1244-6. PubMed ID: 17431015
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Minister rules out use of Avastin over Lucentis for wet AMD.
    Kmietowicz Z
    BMJ; 2015 Apr; 350():h2050. PubMed ID: 25882175
    [No Abstract]   [Full Text] [Related]  

  • 12. [Age-related visual loss].
    Neubauer AS; Kernt M
    MMW Fortschr Med; 2013 Feb; 155(2):36-7. PubMed ID: 23573743
    [No Abstract]   [Full Text] [Related]  

  • 13. [Treatment of neovascular age-related macular degeneration: an unresolved matter].
    Flores-Moreno S; Bautista-Paloma J
    Arch Soc Esp Oftalmol; 2008 Jul; 83(7):405-6. PubMed ID: 18592439
    [No Abstract]   [Full Text] [Related]  

  • 14. Should Avastin be used to treat age-related macular degeneration in the NHS?--Yes.
    Raftery J; Dent L
    Eye (Lond); 2009 Jun; 23(6):1247-9. PubMed ID: 19407834
    [No Abstract]   [Full Text] [Related]  

  • 15. A licence to cure.
    Aronson JK; Ferner RE
    BMJ; 2015 Apr; 350():h1723. PubMed ID: 25834026
    [No Abstract]   [Full Text] [Related]  

  • 16. Bevacizumab versus ranibizumab: why are we not playing the joker?
    Banfi R; Attanasio F; Palazzi N; Colombini S; Falai T; Cecchi M; Virgili G
    Int J Clin Pharm; 2013 Aug; 35(4):507-9. PubMed ID: 23625322
    [No Abstract]   [Full Text] [Related]  

  • 17. Treatment of exudative age-related macular degeneration: many factors to consider.
    Olsen TW
    Am J Ophthalmol; 2007 Aug; 144(2):281-3. PubMed ID: 17659955
    [No Abstract]   [Full Text] [Related]  

  • 18. A clearer view of evidence in treating macular degeneration: off-label policies and independent research.
    Formoso G; Marata AM; Magrini N; Bero L
    Cochrane Database Syst Rev; 2014 Sep; 2014(9):ED000090. PubMed ID: 25228121
    [No Abstract]   [Full Text] [Related]  

  • 19. AMD: out of sight out of mind.
    Pountney D
    Nurs Older People; 2007 Dec; 19(10):16-9. PubMed ID: 18220063
    [No Abstract]   [Full Text] [Related]  

  • 20. The ranibizumab saga of drug profiteering.
    Lee AC; Radford J
    BMJ; 2008 Sep; 337():a1532. PubMed ID: 18768564
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.